Aleksandra Stańczak at the opening of the Early Phase Trial Oncology Ward in Warsaw

On 29 June this year the first Early Phase Trial Oncology in Poland was opened in the Maria Skłodowska-Curie Institute of Oncology in Warsaw. During the scientific session, Aleksandra Stańczak, MD - leader of the Oncology Research group - presented the following project: Celonko - an innovative anti-FGFR therapy for patients with urinary bladder, lung and stomach cancer. Celon Pharma S.A. implements this project as part of a scientific consortium with i.a. the Maria Skłodowska-Curie Institute of Oncology in Warsaw. The Celonko project is co-financed from the STRATEGMED II programme. The total cost of the CELONKO project is PLN 54,717,125, of which PLN 38,613,623 is financed by the National Centre for Research and Development.
(photo: Marek Fijałkowski)